hepatitis B

Vaccitech plc (NASDAQ: VACC) has announced an interim analysis of safety and efficacy data of VTP-300 from the HBV002 study, including a review of surface antigen (HBsAg) levels in chronic Hepatitis B patients. Data from an interim analysis of immunogenicity and safety in Groups 1...

Arbutus Biopharma Corporation (NASDAQ: ABUS) has announced preliminary data from its Phase 1a/1b trial of AB-836, an oral hepatitis B virus (HBV) capsid inhibitor that interacts with HBV core protein, which in turn is required for viral replication. Arbutus shares are soaring after...

The FDA has approved VBI Vaccines Inc's (NASDAQ: VBIV) PreHevbrio [Hepatitis B Vaccine (Recombinant)] to prevent the infection caused by all known subtypes of hepatitis B virus (HBV) in adults age 18 years and older.  PreHevbrio contains the S, pre-S2, and pre-S1 HBV...

The United States Patent and Trademark Office has issued a notice of patent allowance to Indaptus Therapeutics Inc's (NASDAQ: INDP) platform technology. The patent provides broad protection for applying the Company's platform technology alone and in combination with...

Assembly Biosciences Inc (NASDAQ: ASMB) has decided to discontinue the development of ABI-H2158 (2158) following the observation of elevated alanine transaminase (ALT) levels consistent with drug-induced hepatotoxicity (liver damage) in the Phase 2 trial. The FDA noted that...

Vir Biotechnology Inc (NASDAQ: VIR) has dosed the first patient in the Phase 2 MARCH trial evaluating VIR-2218 in combination with VIR-3434 to treat patients with chronic hepatitis B virus (HBV) infection. The combination treatment is designed to achieve a functional cure (defined...

Enochian BioSciences Inc (NASDAQ: ENOB) has announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus (HBV) infection. Written comments are expected this Fall. The Pre-IND request was made based on promising data...

Arbutus Biopharma Corporation (NASDAQ: ABUS) announced the presentation of five abstracts at the European Association for the Study of the Liver International Liver Congress for AB-729 in chronic hepatitis B and AB-836 programs. AB-729 demonstrated robust mean HBsAg reduction across all...

This week could see up to nine companies price their IPOs. Here is a look at the companies looking to go public this week. Codiak Biosciences: Clinical stage biopharmaceutical Codiak Biosciences (NASDAQ: CDAK) plans to sell 5.5 million shares at a price point of $14 to $16. The...

Arbutus Biopharma Corp (NASDAQ: ABUS) stock has gained 80 percent since the turn of the year, and B. Riley FBR dropped its bullish stance Friday in the wake of the rally.   The Analyst B. Riley FBR's Madhu Kumar downgraded Arbutus Biopharma from Buy to Neutral with an unchanged $...

Assembly Biosciences Inc (NASDAQ: ASMB) made a poster presentation of interim results from two early-stage studies for its ABI-H073, a hepatitis B virus core protein allosteric modulator, at the EASL International Liver Congress 2018 in Paris. The Analyst Chardan analyst Gbola Amusa...

What Happened Dynavax Technologies Corporation (NASDAQ: DVAX) traded up 3.7 percent Wednesday after management announced the Centers for Disease Control and Prevention will recommend HEPLISAV-B as an adult vaccination for hepatitis B. The official nod from the Advisory Committee on Immunization...

Nasdaq halted Dynavax Technologies Corporation (NASDAQ: DVAX) trading for the entirety of Friday’s session -- both before and after an announcement of regulatory progress for the company’s Hepatitis B vaccine, HEPLISAV-B. Shortly after 3p.m. ET, it was announced that The Vaccines and...

A few months ago, PharmAthene, Inc. (NYSE: PIP) and Altimmune announced they were merging in an all-stock transaction to create an integrated and diversified immunotherapeutics company. PharmAthene shareholders will decide whether the merger actually goes through on May 4. Ahead of the vote, and...

Benzinga recently had the opportunity to pick the brain of Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) CEO Douglas M. Fambrough, Ph.D. We first looked into what RNA interference is and how it's used to treat genetic diseases. We then talked products, partnerships and stock performance and...